



# Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation

Huseyin Naci <sup>1,2,3,4</sup> Mahnum Shahzad <sup>1,3,4</sup> Peter Murphy <sup>1,5</sup> Yichen Zhang, <sup>1,6</sup> Rebecca Costa, <sup>3</sup> Joseph S Ross <sup>7,8,9,10</sup> Anita K Wagner <sup>1,3,4</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/bmjmed-2025-001934>).

For numbered affiliations see end of article.

Correspondence to: Dr Huseyin Naci; [h.naci@lse.ac.uk](mailto:h.naci@lse.ac.uk)

Cite this as: *BMJ MED* 2025;4:e001934. doi:10.1136/bmjmed-2025-001934

Received: 23 July 2025

Accepted: 24 October 2025

## ABSTRACT

**OBJECTIVE** To evaluate the survival gains and additional Medicare spending associated with early access to new cancer drugs granted accelerated approval by the US Food and Drug Administration (FDA), compared with access to cancer drugs following completion of confirmatory trials.

**DESIGN** Retrospective observational study and economic evaluation.

**SETTING** US Medicare programme, which provides health insurance for adults aged 65 years and older.

**PARTICIPANTS** Medicare beneficiaries who received new cancer drug indications from the time of FDA accelerated approval to conversion to regular approval, withdrawal from the market, or 31 December 2020.

**INTERVENTIONS** Use of cancer drugs for indications that initially received FDA accelerated approval between 1 January 2012 and 31 December 2020.

**MAIN OUTCOMES AND MEASURES** Primary outcomes were life year gains and additional Medicare spending associated with cancer drug indications that initially received FDA accelerated

approval. Each indication's overall survival benefit to patients, if present, was determined, and a partitioned survival model was developed to estimate the life year gains and incremental Medicare spending attributable to early drug access. Beneficiaries who received accelerated approval indications were followed for survival and spending outcomes until 31 December 2022.

**RESULTS** An estimated 178 708 Medicare beneficiaries received access to 90 new cancer drug indications from the time of accelerated approval to conversion to regular approval, withdrawal from the market, or 31 December 2020. Seventeen per cent of beneficiaries (n=30 374) received drugs for indications that were ultimately withdrawn, 5574 (3.1%) received drugs for indications that remained under accelerated approval, and 142 760 (79.9%) received drugs for indications that were subsequently converted to regular approval. Overall, 80 885 (45.3%) beneficiaries received drugs for indications that provided an overall survival benefit to patients. Between 2012 and 2022, use of these drug indications was associated with an estimated 76 164 life years gained. Only three accelerated approvals (nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung cancer, and pemetrexed to treat non-small cell lung cancer) accounted for 68.4% (n=52 107 years) of the total life year gains. The estimated additional cost of early access to these drugs to Medicare was \$20.1bn (£15.4bn; €17.4bn) corresponding to a mean spending of \$263 371 (95% confidence interval \$180 139 to \$373 884) per life year gained. Additional mean Medicare spending per life year gained ranged from \$25 947 (\$18 174 to \$39 829) for melanoma indications to \$4.5m (\$3.1m to \$12.2m) for breast cancer indications.

**CONCLUSIONS** This study examined the trade-off between the benefits of earlier access to cancer drugs through the FDA's accelerated approval pathway and the uncertainty surrounding their clinical efficacy at the time of market entry. Accelerated approval yielded uneven survival returns, with a small number of drugs accounting for the majority of life year gains. Medicare incurred substantial costs for treatments that, in over half of cases, did not provide an overall survival benefit to patients.

## WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Cancer drugs account for the majority of US Food and Drug Administration (FDA) accelerated approvals, a pathway that facilitates earlier access to new drugs based on trials using surrogate markers as efficacy endpoints
- ⇒ The implementation of the accelerated approval pathway has been controversial for cancer drugs, because most drug indications have not demonstrated overall survival benefits in confirmatory trials

## WHAT THIS STUDY ADDS

- ⇒ This analysis examines the trade-off between the benefit of early access to cancer drug indications against the costs to Medicare associated with greater uncertainty around the drug's efficacy
- ⇒ Most Medicare beneficiaries received treatments that provided minimal or no overall survival gains
- ⇒ The additional Medicare spending per life year gained was substantial and varied considerably across cancer types

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY

- ⇒ Timely completion of confirmatory trials measuring overall patient survival, followed by appropriate regulatory action, would help direct Medicare funds toward treatments with proven clinical benefits
- ⇒ The FDA should clearly communicate the degree of uncertainty about drugs granted accelerated approval to support informed decision making by clinicians and patients

## Introduction

The US Food and Drug Administration (FDA) faces a challenge in balancing timely access to new therapeutics with the need for robust evidence demonstrating their safety and efficacy. The accelerated approval pathway, introduced by the FDA in 1992, was designed to expedite access to drugs for patients with serious conditions and unmet medical needs.<sup>1</sup> This pathway allows drug approval based on surrogate endpoints—interim measures such as laboratory tests or imaging results—that are reasonably likely to predict clinical benefit.<sup>2</sup> While surrogate endpoints enable faster clinical trial testing and drug development,<sup>3</sup> they introduce substantial uncertainty regarding the clinical benefits of approved drugs, as positive outcomes from trials using surrogate endpoints may not reliably correlate with how patients feel, function, or survive.<sup>4-8</sup> Characteristics of clinical studies supporting accelerated approvals also contribute to this uncertainty; they often lack control groups, have small patient populations, and rarely use features like blinding.<sup>6-8</sup>

To reduce this uncertainty, the FDA requires post-marketing confirmatory trials to verify the clinical benefit of drugs granted accelerated approval. However, the implementation of this requirement has been inconsistent:<sup>9-12</sup> between 1992 and 2020, nearly half of the drug indications that have received accelerated approval did not have completed confirmatory trials.<sup>13</sup> Trial completion is often delayed,<sup>14</sup> and some drugs without verified benefit remain on the market for extended periods. Even when confirmatory trials are completed, concerns persist about the quality of evidence used to determine clinical benefit. In more than half of accelerated approval, surrogate endpoints were used not only to grant accelerated approval but also to establish benefit in confirmatory trials.<sup>15</sup> Enforcing regulatory action after the completion of confirmatory trials has also been delayed, including in cases where trials failed to demonstrate clinical benefit.<sup>16</sup>

The implementation of the accelerated approval pathway has been particularly controversial for cancer drugs, which accounted for more than 80% of accelerated approvals between 2010 and 2020. A weak to moderate association exists between surrogate endpoints used in cancer drug trials, including patient response rate and progression-free survival, and patient survival or quality of life.<sup>17-20</sup> Thus, drugs that have positive results in trials using surrogate endpoints often do not confer survival gains or improvements in how patients feel or function.<sup>21</sup> Between 1992 and 2017, only 20% of cancer drug indications judged to have verified clinical benefit by the FDA provided an overall survival benefit to patients.<sup>22</sup> Moreover, 22% of cancer drug indications with accelerated approvals between 2013 and 2023

were subsequently withdrawn from the market because of a lack of evidence for their clinical benefit.<sup>23</sup>

The accelerated approval pathway must balance the benefits of early patient access to drugs against the risks of approving drugs with uncertain evidence for their efficacy.<sup>24</sup> The FDA states that this pathway has enabled cancer drugs to enter the market sooner than they otherwise would.<sup>3 25 26</sup> Earlier access has benefitted some patients for whom the survival gains associated with treatment were substantial, such as those treated with imatinib, which improved outcomes for patients with chronic myeloid leukaemia.<sup>27</sup> However, not all patients benefit from the accelerated approval pathway: some receive drugs later shown to lack clinical benefit, and in some cases, drugs that may cause harm.<sup>28</sup> Early access to expensive new cancer treatment also incurs substantial healthcare costs for patients and the healthcare system.<sup>29</sup>


Earlier research has not evaluated the cost-benefit balance of the accelerated approval pathway. It is not known whether the FDA strikes an optimal balance between expedited approval and demonstration of efficacy for new cancer drugs that initially receive accelerated approval. The cost-benefit balance of the accelerated approval pathway is particularly important for the federal Medicare programme, which provides health insurance for Americans aged 65 years and older. Medicare consists of two main components: traditional Medicare, administered by the government, and Medicare Advantage, offered by private insurers.<sup>30</sup> More than 50% of US cancer diagnoses are received by Medicare beneficiaries, with substantial cost implications to the programme.<sup>31</sup> Between 2016 and 2020, the share of Medicare drug spending on cancer drugs increased from 33.7% to 43.1% in part B, which covers injectable drugs, and from 9.1% to 13.2% in part D, which covers outpatient drugs.<sup>32</sup> Spending for drugs with accelerated approvals comprises a growing portion of this increase in Medicare's overall cancer drug spending.<sup>33</sup>

In this study, we evaluated the expected patient survival benefits and additional Medicare spending associated with early access to new cancer drug indications granted accelerated approval by the FDA, compared with access following regular approval.

## Methods

### Overview

We implemented our methodological approach in five steps (figure 1). Firstly, we identified the cancer drug indications that initially received FDA accelerated approval and determined their current status: the drugs either remained under accelerated approval, were converted to regular approval, or had been withdrawn from the



**Figure 1 | Overview of our methodological approach to evaluating survival gains and additional Medicare spending associated with early access to new cancer drugs through FDA accelerated approval pathway. AA=accelerated approval. CMS=Centres for Medicare & Medicaid Services**

market. The period between accelerated approval and conversion to either regular approval or withdrawal represented the period of early access, during which a patient would have access to a drug which would not have been possible without the accelerated approval pathway (online supplemental appendix figure 1). Secondly, we estimated the number of patients who had gained access to new cancer drugs for indications that had initially received FDA accelerated approval. Thirdly, we determined whether cancer drug indications that had initially been granted accelerated approval had demonstrated overall survival benefit to patients compared with control treatments in clinical trials. We then collected Medicare spending data, and finally, we developed a decision analytical model to estimate life year gains to patients and additional Medicare spending incurred during the early access period for cancer drug indications that had initially received accelerated approval. In

the model, patients receiving treatment with accelerated approval drugs could accrue survival benefits, and could also incur additional Medicare spending compared with patients receiving control treatments during the same period.

The study period began in 2012, the first year for which Medicare spending data were available. We considered drugs given accelerated approval up to 31 December 2020 to ensure that we could observe at least four years of follow-up data on overall survival from confirmatory trials on overall survival (up to 30 November 2024). Beneficiaries who gained early access to new cancer drug indications were followed up until 31 December 2022 (online supplemental appendix figure 2).

Because our analysis compared accelerated approval of cancer drug indications with regular approval, rather than evaluating a specific intervention, no

single reporting guideline directly applied to our study. However, our reporting aligns with the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement.<sup>34</sup>

### Sample identification and selection

We identified cancer drug indications with FDA accelerated approval from 1 January 2012 to 31 December 2020 using the Center for Drug Evaluation and Research list of Drug and Biologic Accelerated Approvals based on a surrogate endpoint. Our sample included original indication approvals for new drugs and supplementary indication approvals for previously approved drugs. The status of accelerated approvals was determined using the Oncology Accelerated Approvals database maintained by the FDA Oncology Center of Excellence. We recorded whether cancer drug indications that initially received accelerated approvals had been verified for clinical benefit by the FDA and converted to regular approval, had been withdrawn from the market, or if confirmatory trials for these indications were ongoing as of 30 November 2024. If applicable, dates of conversion to regular approval or dates of withdrawal were recorded.

### Estimation of patient numbers

We estimated the number of patients who received new cancer drugs for indications that initially received FDA accelerated approval through conversion to regular approval, withdrawal from the market, or by 31 December 2020. Since 2012, the Centers for Medicare & Medicaid Services (CMS) has reported the total number of Medicare beneficiaries per year using individual drugs in part B insurance and part D.<sup>35 36</sup> However, data for indication-specific use are not publicly accessible.

To estimate the proportion of Medicare beneficiaries who used new cancer drugs for indications granted FDA accelerated approval, we developed algorithms using claims data.<sup>37 38</sup> We based our estimation of indication-specific use on Medicare Advantage plans offered by a large US commercial health insurer, and then extrapolated the proportion of use attributable to each indication for each drug to all Medicare claims, as in previous studies.<sup>38</sup>

We assumed that usage patterns of accelerated approval drugs are broadly similar between beneficiaries with Medicare Advantage and those with traditional Medicare. Although these populations differ by geographical distribution, race and ethnicity, income, and education level,<sup>39</sup> earlier research has found no systematic differences between them in cancer prevalence or spending on injectable drugs.<sup>40 41</sup>

We used Optum Insights Clininformatics to extract the annual de-identified medical and pharmacy claims for each drug from 1 January 2012 to 31 December 2020. To link each patient to a specific

indication, we identified the proportion of patients starting treatment with the drug for a given indication each year, which involved first distinguishing patients who were new to the treatment from those who had used the drug previously. For the subpopulation of new users, we then calculated indication-specific proportions using data from the first claim for each drug.

We based our algorithms to estimate indication-specific use on ICD-9 (international classification of diseases, 9th revision) and ICD-10 (10th revision) codes and label-indicated concomitant medications (defined as treatments used within 30 days of the dispensing of interest) (online supplemental appendix table 1). When multiple indications were present within the same set of ICD-9 and ICD-10 codes and concurrent treatments, we also used information on label-indicated prior therapies to identify indication-specific use. In instances where a single dispensing of a particular drug could be used to treat multiple indications, we attributed the drug's use to the indication associated with an overall survival benefit to the patient. If no indication had an overall survival benefit, we attributed use to the indication with the earliest approval date, and tested the sensitivity of our findings to this assumption.

After calculating the proportion of users receiving new cancer drugs for indications that initially received FDA accelerated approval, we applied the proportion to the total numbers of Medicare beneficiaries receiving each drug in CMS data. For part D, we used the total number of beneficiaries, as reported by CMS. For part B, CMS data include only traditional Medicare. We therefore adjusted the CMS data for part B using publicly available enrolment proportion to account for Medicare Advantage coverage, similar to previous studies.<sup>32</sup>

For example, we estimated that in 2013, the first year with CMS data available for brentuximab vedotin, 85% of all patients prescribed this drug were new users, and 50% of those new users received it for an indication with accelerated approval. CMS reported that 645 Medicare beneficiaries received brentuximab vedotin in 2013; we estimated that 548 (85%) of these were new users, and 274 (50%) of these 548 patients were treated for the accelerated approval indication. Because this is a part B drug and CMS data reflect only traditional Medicare, we adjusted for the fact that traditional Medicare accounted for 72% of total Medicare enrolment in 2013. The adjusted denominator was therefore 896, and an estimate of 381 new patients used the drug for the accelerated approval indication.

Our stepwise approach was implemented in Stata (version 18) to estimate the total annual number of patients receiving new cancer drugs for indications that initially received FDA accelerated approval across all Medicare beneficiaries.

### Data extraction from clinical trials

For each indication, we reviewed section 14 (clinical studies) of the drug's labelling approved by the FDA at the time of accelerated approval to identify the pivotal trial or trials supporting the FDA's decision. We then systematically reviewed approval letters in the Drugs@FDA database to identify post-marketing confirmatory trials requested at the time of accelerated approval, and their projected completion dates. We used national clinical trial (NCT) numbers to search ClinicalTrials.gov for each confirmatory trial and identify linked articles. When NCT numbers were unavailable, we searched ClinicalTrials.gov using the drug name and approved indication. We also searched company press releases and industry news outlets to identify confirmatory trials.

For indications that were converted to regular approval, we identified completed confirmatory trials by reviewing FDA approved labelling at the time of conversion to regular approval. We extracted information on treatment and control groups, study design, primary endpoint or endpoints, and results from pivotal trials and confirmatory trials. All data were independently extracted by two investigators and confirmed by a third.

We assessed the availability of overall survival results for each indication, and extracted data on the median duration of overall survival in treatment and control groups, hazard ratios, and 95% confidence intervals (CI), using the most recent results available from confirmatory trials. When the median was not reached in clinical trials, we extracted data on survival rates up to the latest available time point. When data on overall survival were not available in confirmatory trials, we used information available from pivotal trials. We categorised each indication based on whether it showed a statistically significant overall survival benefit, as in earlier studies.<sup>42 43</sup> We also extracted data on progression-free survival using this same approach.

### Calculation of Medicare spending

We used publicly available prescription drug event data from the CMS drug spending dashboards to evaluate Medicare spending for cancer drug indications that were initially given FDA accelerated approval, as in earlier research.<sup>33 44</sup> We calculated the difference in Medicare spending between the treatment strategy (including the accelerated approval drug) and the standard of care strategy (without the accelerated approval drug) as additional spending, as tested in the control arms of clinical trials.

We first identified the drugs included in the experimental and control arms of clinical trials. When only single arm trials were available, we assumed no available treatments in our base case analysis. For each drug, we extracted annual average spending per beneficiary using spending dashboards for either part B or part D. When drugs were listed in both parts

B and D, we assigned them to either part B or part D following the approach used in previous studies.<sup>32</sup> When spending data for different formulations of the same drug were available, we calculated a weighted average using annual beneficiary numbers. We adjusted spending for inflation to 2022 US dollars, based on the US Consumer Price Index for Medical Care.<sup>45</sup>

For each indication, we then separately summed up the average annual Medicare spending per beneficiary for all drugs in the experimental arms and those in the control arms. The difference between these sums represented the additional yearly spending allocated to drugs with earlier patient access.

### Modelling to estimate life year gains and additional spending

To estimate life year gains and additional spending associated with new cancer drug indications with FDA accelerated approval, we developed a partitioned survival model in Microsoft Excel with two states: alive and dead (online supplemental appendix figure 3).<sup>46</sup> Partitioned survival models are often used to evaluate the costs and benefits of treatments for advanced and metastatic cancers.<sup>47 48</sup> Our model incorporated monthly cohorts of patients starting treatment with either the accelerated approval drug or the usual standard of care, from the date of accelerated approval to the end of 2020, with patient follow-up extending to December 2022.

We tracked life year gains associated with the accelerated approval drug and the control treatment based on overall survival data extracted from clinical trials. We estimated the proportion of surviving patients over time by fitting an exponential curve to the median survival data, a pragmatic approach for long term data extrapolation in the absence of individual participant level data.<sup>49 50</sup> The exponential distribution is widely used in economic evaluations of cancer treatments.<sup>51 52</sup> We assumed proportional hazards throughout the model to reflect a constant treatment effect on patient survival.

To maximise use of the available data, the model incorporated the most recent overall survival data, irrespective of statistical significance. By multiplying the proportion of living patients by the total number of patients in each month, the model accumulated the months lived with the accelerated approval drug versus months lived with the control treatment.

Patients who were alive and receiving treatment, either with the accelerated approval drug or the control treatment, accrued additional spending in the Medicare programme. The model had a payer perspective, because we only considered Medicare spending in our study. The model estimated the proportion of patients remaining on treatment (the accelerated approval drug or the control treatment) over time by fitting an exponential curve to the progression-free survival data extracted from clinical

trials. Given the retrospective nature of the analysis (estimating life year gains and costs up to December 2022), the model did not discount life year gains or additional spending.

We compared the estimated spending per life year gained against commonly used US cost effectiveness thresholds, which range from \$100 000 (£75 991; €86 399) to \$150 000 per quality adjusted life year (QALY) or equal value life year gained, as recommended by the Institute for Clinical and Economic Review.<sup>53 54</sup> Since no formal threshold exists for life years gained, we use this range as a proxy for the amount a decision maker might be willing to pay for a drug with associated survival benefits.

To estimate uncertainty, we performed probabilistic sensitivity analyses using Monte Carlo simulations with 10 000 iterations per drug indication. Overall survival and progression-free survival parameters were modelled using normal distributions, while costs were modelled using a gamma distribution. Results were reported as 95% CIs.

### Scenario analyses

To assess the robustness of our findings against the data limitations, we performed several scenario analyses. The scenario analyses included varying comparator treatments for indications supported by single arm trials or trials with multiple comparators (which affected estimated accrued additional spending), reallocating drug use across similar indications to account for limitations in the claims data (which influenced both Medicare spending and patient survival outcomes), and modelling patient survival benefits in the absence of overall survival data (which affected estimated life years gained). We also varied the period of time that constituted early access, which we hypothesised would have the greatest impact on our results, as this assumption applied to all indications in our sample.

In the first set of scenario analyses, we tested the sensitivity of our findings to different spending estimates, accounting for the various drugs included in the treatment and control arms of clinical trials. In the base case analysis, we assumed no relevant comparator treatment when a drug was evaluated in a single arm trial. In the analysis (spending scenario 1), we identified potentially relevant comparators by searching ClinicalTrials.gov for the drug name and its accelerated approval indication, and by assessing FDA medical review documents available on the Drugs@FDA data repository for references to existing alternative treatments. Furthermore, we varied the additional spending for the treatment and control arms by creating high cost (spending scenario 2) and low cost (spending scenario 3) scenarios, especially when the control arm allowed for physician's choice.

In the second set of analyses, we allocated drug use to different indications when our algorithms (based on claims data) could not clearly distinguish

between a drug's similar indications. For example, nivolumab had three accelerated approvals for metastatic melanoma. In our base case, we allocated all observed nivolumab use to the indication with the most substantial overall survival gain in patients. In scenario analyses (utilisation scenarios 1 and 2), we tested the impact of allocating the observed drug use to indications with less substantial survival gains.

In the third set of scenario analyses, we adopted different assumptions about the survival benefits in indications with no overall survival data. In our base case analysis, we assumed patients who received drugs for indications that had no overall survival data (eg, owing to the single arm trial design) derived no life year gains from earlier access. When data on overall survival were not available, we identified existing systematic reviews of trial level meta-analyses that evaluated the association between the surrogate marker(s) used as the primary efficacy endpoint(s) in key trials or confirmatory trials, and overall survival for the same clinical indication.<sup>17 18</sup> When available, we used linear regression equations reported in trial level meta-analyses to estimate the magnitude and statistical significance of overall survival results, using available data from surrogate endpoints (survival scenario 1). In a separate analysis, we assumed that the median overall survival benefit of indications with verified clinical benefit applied to similar indications still undergoing confirmatory trials (survival scenario 2).

In the fourth set of scenario analyses, we varied the definition of early access to reflect the median duration of a confirmatory trial until its completion (duration of early access scenario 1)<sup>55</sup> and the time until the original projected completion date of a confirmatory trial (duration of early access scenario 2).

### Patient and public involvement

No members of the public were formally involved in the design or implementation of this study, because no funding was available for public or patient involvement. However, we have discussed our findings with members of the National Breast Cancer Coalition, a network of patient organisations from across the US interested in improving the FDA's regulation of pharmaceuticals. We have included their comments about the policy and practice implications of our findings in the discussion. Results will be shared via the press and public policy offices at the London School of Economics and Political Science, Harvard Pilgrim Health Care Institute, University of York, Peking University, and Yale University. Typical mediums include press releases, social media posts (X, Bluesky, and LinkedIn), and policy briefs for policy makers. We will continue engaging with members of the National Breast Cancer Coalition to develop and publish a plain language summary of the study and its implications for the public and policy makers.

**Table 1 | Characteristics of cancer drug indications included in study**

Indications (n=90)	No (%)
<b>Accelerated approval indication</b>	
Lymphoma	15 (16.7)
Lung cancer	13 (14.4)
Leukaemia	9 (10.0)
Urothelial carcinoma	8 (8.9)
Breast cancer	6 (6.7)
Melanoma	6 (6.7)
Multiple myeloma	5 (5.5)
Hepatocellular carcinoma	4 (4.4)
Other*	24 (26.7)
<b>Accelerated approval status</b>	
Verified†	51 (56.7)
Ongoing	23 (25.6)
Withdrawn	16 (17.8)
<b>Availability of overall survival benefit</b>	
Evidence of overall survival benefit	27 (30.0)
No evidence of overall survival benefit	30 (33.3)
Unknown	33 (36.7)

Percentages may not add up to 100% owing to rounding.

\*Includes: cervical cancer (n=1), cholangiocarcinoma (n=1), colorectal cancer (n=3), endometrial carcinoma (n=2), gastric or gastro-oesophageal junction adenocarcinoma (n=1), head and neck squamous cell carcinoma (n=1), Merkel cell carcinoma (n=2), ovarian cancer (n=2), prostate cancer (n=1), sarcoma (n=2), Kaposi's sarcoma (n=2), thyroid cancer (n=2), and tumour agnostic cancers (n=4). Online supplemental appendix includes the list of cancer drug indications with accelerated approvals.

†Cancer drug indications judged to have verified clinical benefit by the US Food and Drug Administration and converted to regular approval.

## Results

### Sample characteristics

Between 2012 and 2020, the FDA granted accelerated approval for 97 cancer drug indications. We excluded seven of these indications for which Medicare spending data were unavailable, corresponding to five drugs, giving a final study sample of 90 indications. Of the 90 indications, 15 (16.7%) were for lymphoma, 13 (14.4%) for lung cancer, nine (10.0%) for leukaemia, eight (8.9%) for urothelial carcinoma, and six (6.7%) for breast cancer (table 1, online supplemental appendix table 1).

Among the 90 indications initially given FDA accelerated approval, 51 (56.7%) were converted to regular approval, 16 (17.8%) were withdrawn from the market, and 23 (25.6%) had post-marketing requirements for ongoing confirmatory trials and remained under accelerated approval (table 1).

Overall, 27 (30.0%) of 90 indications that initially received FDA accelerated approval demonstrated an overall survival benefit to patients in randomised controlled trials (online supplemental appendix table 2 and 3). Of the 51 indications converted to regular approval, 25 had evidence of overall survival benefit to patients, while the remaining 26 were converted to regular approval based on surrogate endpoints: 15 indications showed no overall survival benefit and the overall survival benefit of the remaining 11 indications was unknown (six due to single arm trial

designs and five due to immature survival data). Two indications remained under accelerated approval that had evidence of overall survival benefit. Randomised controlled trials found evidence of no overall survival benefit for 30 (33.3%) indications, including 11 that were converted to regular approvals. Overall survival benefit was unknown for 33 (36.7%) indications: 11 because of single arm trial designs, 9 because of immature survival data, and the remaining 13 because of other reasons.

### Use of cancer drugs


An estimated 178 708 Medicare beneficiaries received early access to new cancer drugs through the FDA's accelerated approval pathway. Overall, an estimated 31 245 (17.5%) beneficiaries received drugs for breast cancer, 30 501 (17.1%) for lung cancer, 22 098 (12.4%) for urothelial carcinoma, 21 695 (12.1%) for melanoma, and 19 455 (10.9%) for multiple myeloma (figure 2).

A total of 142 760 (79.9%) beneficiaries received drugs for indications that were ultimately converted to regular approval, 5574 (3.1%) for indications still under accelerated approval, and 30 374 (18.0%) for indications that were later withdrawn. The number of beneficiaries receiving treatment for indications that were withdrawn has increased in recent years, comprising 25.8% of beneficiaries with early access to cancer drugs in 2020 (figure 3).

Among all beneficiaries who received the new cancer drugs for accelerated approval indications, 80 885 (45.3%) received them for indications that were eventually shown to have overall survival benefit, whereas 86 085 (48.2%) received the new drugs for indications with no overall survival benefit, and 11 738 (6.5%) for indications where overall survival benefit was unknown. In 2020, 17 455 beneficiaries received drugs for indications that had no overall survival benefit, nearly twice as many as the 9517 beneficiaries who received drugs for indications that did show an overall survival benefit (figure 3).

### Life year gains and additional spending

Our model, which applied trial data to Medicare drug use, estimated that early access to cancer drugs for indications that initially received accelerated approval resulted in 76 164 (95% CI 71 520 to 80 658) life years gained by Medicare beneficiaries between 2012 and 2022. Life year gains in patients with melanoma accounted for an estimated 34 965 (95% CI 28 425 to 42 497; 45.5%) of the total number of life years gained by Medicare beneficiaries, followed by patients with lung cancer (22 286 life years; 95% CI 21 282 to 22 765; 29.4%), and patients with multiple myeloma (8159 life years; 95% CI 7929 to 8220; 10.8%; figure 4). The use of nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung cancer, and pemtrexed




**Figure 2 |** Estimated number of Medicare beneficiaries who accessed new cancer drugs for indications that initially received US Food and Drug Administration accelerated approval (by cancer type) and used the new drugs in the period from accelerated approval to conversion to regular approval, withdrawal, or 31 December 2020. Other=cervical cancer; cholangiocarcinoma; colorectal cancer; endometrial carcinoma; gastric or gastro-oesophageal junction adenocarcinoma; head and neck squamous cell carcinoma; Merkel cell carcinoma; ovarian cancer; prostate cancer; sarcoma; Kaposi's sarcoma; thyroid cancer; and tumour agnostic cancers

in combination with pembrolizumab and carboplatin for non-squamous, non-small cell lung cancer accounted for 52 107 (68.4%) of life years gained by beneficiaries.


Between 2012 and 2022, nearly half (n=41, 45.6%) of new cancer drug indications initially given accelerated approval resulted in no life year gains to patients (figure 5). Thirty five (38.9%) indications resulted in estimated life year gains from 0.01 to 0.5 years per patient, 10 (11.1%) indications gave life

year gains of 0.5 years or more per patient, and four resulted in life year losses to the patient.

Use of these cancer drugs was estimated to cost the Medicare programme \$20.1bn (95%CI \$12.9bn to \$30.2bn) in additional spending, compared with standard of care treatment (comparator treatments listed in online supplemental appendix table 4). Additional Medicare spending for drugs indicated for breast cancer accounted for \$7.4bn (\$4.8bn to \$10.6bn, 36.8%) of the total additional spending,



**Figure 3 |** Estimated number of Medicare beneficiaries who accessed new cancer drugs for indications that initially received US Food and Drug Administration (FDA) accelerated approval according to (top) accelerated approval status and (bottom) availability of overall survival benefit. Verified=cancer drug indications with FDA verified clinical benefit and converted to regular approval. Nearly half of these indications did not have evidence of overall survival benefit to patients



**Figure 4 |** Estimated cumulative life year gains to Medicare beneficiaries who used new cancer drugs for indications initially given accelerated approval by the US Food and Drug Administration, by cancer type. Lymphoma indication category is not shown, because new drug use in lymphoma indications resulted in no life year gains but resulted in life year losses to patients

followed by \$3.1bn (\$2.0bn to \$4.5bn, 15.4%) for multiple myeloma, \$2.8bn (\$1.8bn to \$4.1bn, 13.9%) for lymphoma, \$2.0bn (\$1.3bn to \$3.0bn, 9.9%) for lung cancer, and \$1.4bn (\$0.9bn to \$1.9bn, 6.9%) for leukaemia (figure 6).

An estimated \$16.6bn (95%CI \$10.7bn to \$25.1bn, 82.6%) of the total additional spending was attributable to indications that were converted to regular approval, while \$2.9bn (\$1.9bn to \$4.2bn, 14.4%) was for indications that were later withdrawn from the market (figure 6). Early access to cancer drugs in indications demonstrated to result in overall survival benefits to patients accounted for an estimated \$6.7bn (\$4.3bn to \$10.1bn, 33.3%) of additional Medicare spending (figure 6). The remaining additional spending was for indications with no overall survival benefit to patients (\$11.9bn, \$7.7bn to \$17.8bn, 59.2%) or indications with unknown overall survival benefit to patients (\$1.4bn, \$0.9bn to \$2.2bn, 7.0%).

Our model estimated the additional Medicare spending per life year gained to be \$263 371 (95%CI \$180 139 to \$373 884), ranging from an additional \$25 947 (\$18 174 to \$39 829) per life year gained for drugs with melanoma indications to \$4.5m (\$3.1m to \$12.2m) per life year gained for drugs with breast cancer indications (figure 7). The additional Medicare spending for lymphoma drug indications (\$9.5m, \$5.1m to \$18.9m) was not associated with life year

gains but was associated with a potential loss of life. Drug indications that were converted to regular approval resulted in an additional cost of \$221 545 (\$153 589 to \$311 417) per life year gained.


#### Scenario analyses

Figure 8 shows the sensitivity of our findings to different assumptions and scenarios. Our findings remained stable across a range of assumptions. Allocating the observed drug use to indications with less substantial survival gains led to higher estimated Medicare spending per life year gained. Capping the duration of early access to 17 months, the median duration of a confirmatory trial, resulted in an estimated cost to Medicare of \$178 728 per life year gained.

#### Discussion

##### Principal findings

Between 2012 and 2020, the FDA's accelerated approval pathway enabled an estimated 178 708 Medicare beneficiaries to gain earlier access to 90 cancer drug indications. This early access was associated with an estimated 76 164 additional life years gained by patients. However, these gains came at a substantial cost: approximately \$20.1bn in additional Medicare spending. On average, the additional cost to Medicare was \$263 371 per life year gained, substantially more than conventional



**Figure 5 |** Estimated life year gains per patient owing to early access to new cancer drugs for 90 indications initially given accelerated approval by the US Food and Drug Administration. Cancer drug indications are ordered by estimated mean life year gains per patient. NSCLC=non-small cell lung cancer. ALK=anaplastic lymphoma kinase




Figure 6 | Estimated additional Medicare spending for new cancer drugs for indications that initially received accelerated approval by the US Food and Drug Administration, according to (top) cancer type, (middle) accelerated approval status, and (bottom) availability of overall survival benefit. OS=overall survival




Figure 7 | Estimated additional Medicare spending and life year gains, by cancer type. Node size is proportional to the number of Medicare beneficiaries receiving access to new cancer drugs for indications that initially received accelerated approval. Blue diagonal line from 0 indicates \$150 000 per life year gained, which is a conventional cut-off value used to define cost effectiveness of healthcare spending in the US; results below the line require spending of less than \$150 000 per life year gained, and are therefore considered more cost effective. Results for lymphoma indications suggest that additional Medicare spending did not provide life year gains but correlated with potential loss of life




Figure 8 | Sensitivity of results on additional Medicare spending per life year gained to different assumptions and scenarios

cost effectiveness thresholds in the US healthcare system.<sup>53 54</sup>

Most beneficiaries received cancer drugs for indications that were eventually converted to regular approval by the FDA; these indications accounted for 79.9% of observed use and 82.6% of additional Medicare spending. Although most early access drug use and additional spending were for indications that were ultimately converted from accelerated approval to regular approval by the FDA, the FDA often converted accelerated approvals to regular approvals without evidence of overall survival benefit to patients, consistent with findings from earlier studies.<sup>22 23</sup> During our study period, only 25 of 51 converted indications had evidence of overall survival benefit.

We found a growing trend in the use of drugs for indications that were later withdrawn following negative confirmatory trials. This trend might reflect declining standards for evidence quality at the time of accelerated approval, delays in completing confirmatory trials, or delays in regulatory action. From 2018 to 2020, about 25% of new cancer drug indications to which patients were given early access were eventually withdrawn. Overall, most access to new cancer drugs through the accelerated approval pathway were in indications that did not demonstrate evidence for a survival benefit to patients within at least four years after approval.

When Medicare beneficiaries derived survival gains from earlier access to new cancer drugs with accelerated approval, the benefit they gained was often small. Only 10 indications resulted in life year gains of six months or more per patient. Three factors determined the magnitude of life year gains: the availability of evidence of overall survival benefit to patients, the length of the period between an indication being given accelerated approval and either conversion to regular approval or withdrawal from the market, and the number of beneficiaries

receiving the treatment during that period. When a drug provided substantial survival benefit to patients, a short interval between accelerated approval and regular approval limited the number of patients who could access the drug earlier than they would have under the standard approval pathway, thereby limiting the life year gains attributable to accelerated approval. Conversely, when a drug did not give survival benefit to patients but remained on the market for a long period before conversion or withdrawal, more patients received the drug without deriving survival benefit. Our findings in relation to new drug indications to treat breast cancer illustrate this: despite three of six breast cancer indications having evidence of overall survival benefit to patients, the average time to conversion or withdrawal was considerably longer for indications without survival benefit to patients (36.4 months) compared to indications with survival benefit (16.3 months). As a result, most instances of early access occurred in indications without survival benefit to patients, resulting in few life year gains attributable to accelerated approval.

Early access through accelerated approval yielded uneven survival outcomes, and Medicare incurred substantial costs for treatments that, in some cases, did not deliver meaningful clinical benefit to beneficiaries. The variation in survival gains across indications meant that substantial Medicare spending sometimes provided patients with minimal or no life year gains. For example, an estimated 31 245 Medicare beneficiaries who received breast cancer drugs between accelerated approval and either conversion to regular approval, withdrawal from the market, or December 2020, gained only 1648 life years by the end of 2022 at an additional cost of \$7.4bn, resulting in an additional cost to Medicare of \$4.5m per life year gained. These findings raise important questions about the value Medicare beneficiaries receive from taxpayer investments and

premiums paid by beneficiaries in cancer drug indications approved through the accelerated approval pathway. Furthermore, resources allocated to treatments with uncertain or limited benefit to patients may divert funding from more effective interventions, or contribute to higher premiums and out-of-pocket costs for beneficiaries, which can have adverse consequences on their health.

### Policy and practice implications

The FDA's accelerated approval pathway was established to provide earlier access to treatments for patients with serious or life threatening conditions, particularly when no alternative treatment options exist. The pathway was designed to balance the potential benefits of earlier treatment access against the risks of clinical uncertainty associated with the use of surrogate endpoints in clinical trials<sup>4</sup>, allowing people to access treatments sooner than they would under traditional approval processes.<sup>26 56</sup> While accelerated approval can lead to the use of treatments that later prove to be ineffective or only marginally effective, some patients with advanced cancers may choose to accept this uncertainty; waiting for complete information on a drug's clinical benefit may harm patients because of delayed access to potentially effective treatments.<sup>57</sup> However, individuals vary in their preferences: many patients express a strong desire for certainty that a cancer drug will improve their chance of survival, and some are willing to wait longer for that evidence.<sup>58</sup> Balancing the risks of clinical uncertainty with the potential harms of delayed access to treatment remains central to the accelerated approval pathway's rationale.<sup>24 59</sup>

A fundamental condition of this pathway is the timely completion of trials after a drug has been given accelerated approval to resolve clinical uncertainty. Our findings suggest that limiting the duration of post-approval trials would better align Medicare spending associated with treatments that offer proven clinical benefit to beneficiaries. Recent initiatives encourage pharmaceutical manufacturers to have confirmatory trials underway at the time of accelerated approval,<sup>60</sup> which is associated with shorter times to conversion or withdrawal.<sup>61 62</sup> However, our findings indicate that timely conversion to regular approval is insufficient if it is based on weak clinical evidence. During our study period, most indications were converted without demonstrating an overall survival benefit to patients.

Surrogate endpoints used to grant accelerated approval should have a reliable and strong association with overall survival benefit, ideally evaluated using meta-analysis methods.<sup>63</sup> Bivariate meta-analysis, which accounts for the correlation between treatment effects and uncertainty around that relationship, is the preferred approach.<sup>64</sup> In addition, confirmatory trials should measure overall survival whenever feasible and avoid features that

may compromise survival assessment (eg, treatment switching).<sup>43</sup> Despite a growing interest in using real world evidence for regulatory decision making, existing claims and electronic health record systems are not sufficient to achieve this,<sup>65</sup> and findings from non-randomised studies may differ from those of randomised trials in unpredictable ways.<sup>66</sup>

The FDA could further strengthen the accelerated approval pathway by improving communication about clinical uncertainty. The agency should explicitly disclose both the nature and magnitude of the uncertainty associated with treatments without verified clinical benefits and the use of surrogate endpoints in trials. Currently, FDA approved labelling for drugs, including those granted accelerated approval, often does not clearly communicate this uncertainty, limiting clinicians' and patients' ability to make fully informed treatment decisions.<sup>67</sup>

Beyond the FDA, other stakeholders can encourage the timely generation of robust evidence for drugs given accelerated approval.<sup>68</sup> Firstly, drug prices should reflect the scale of clinical uncertainty:<sup>29</sup> currently, no consistent association exists between a drug's price and its demonstrated clinical benefit.<sup>69</sup> Even when confirmatory trials report improvements in overall survival, prices for cancer drugs granted accelerated approval do not increase accordingly, thus pharmaceutical companies are not financially incentivised to provide evidence on overall survival.<sup>70</sup> CMS could implement reimbursement policies that lower payment rates until drugs demonstrate clinical benefit, thereby encouraging drug manufacturers to conduct rigorous confirmatory trials.<sup>71 72</sup> Secondly, clinical practice guidelines should communicate the uncertainty of evidence supporting accelerated approvals more effectively. At present, guidelines quickly incorporate recommendations for drugs with accelerated approval indications, facilitating their rapid uptake in clinical practice.<sup>73 74</sup> However, these guidelines do not always indicate when there is prolonged uncertainty about a drug's benefit to patients, nor when a drug indication has been withdrawn,<sup>73 75</sup> which can lead to continued patient exposure to ineffective treatments and undermine trust in clinical recommendations.

These challenges are not confined to the US healthcare system, and regulatory decisions made by the FDA often influence drug availability and clinical practice in other countries. Our findings have implications beyond the US;<sup>76 77</sup> drugs given FDA accelerated approval may also receive marketing authorisation by regulatory agencies in other settings, but without similar requirements for confirmatory trials after the drug is marketed. For example, some indications that initially received FDA accelerated approval may not receive conditional marketing authorisation by the European Medicines Agency and therefore may not be required to verify clinical benefit in the same way.<sup>78</sup> As a result, clinical uncertainty may persist for

longer periods in settings outside of the US, further complicating decisions to fund and use these new treatments in other health systems.<sup>79</sup> In some cases, drug indications withdrawn in the US following confirmatory trials with negative results remain available elsewhere.<sup>80</sup>

### Comparison with other studies

Earlier studies have described the characteristics of pivotal trials and confirmatory trials,<sup>15 25</sup> evaluated the duration until completion of confirmatory trials (and subsequent conversion to regular approval or withdrawal),<sup>12 14</sup> documented overall survival benefits,<sup>16 22 23</sup> and quantified spending associated with accelerated approvals.<sup>33 37 44 81 82</sup> Our study offers a novel contribution to the literature by bringing together these strands and building on previous analyses to provide a comprehensive evaluation of the accelerated approval pathway for cancer drugs.

Our findings differ from those of a recent industry sponsored study, which estimated that early access to cancer drugs resulted in an estimated 263 000 life year gains in the US.<sup>83</sup> This study focused on a selected subset of accelerated approvals after excluding 47% of eligible indications, estimated patient numbers using a proprietary database without providing details, identified overall survival benefits using data from randomised controlled trials and non-randomised studies (which may differ in their findings in unpredictable ways),<sup>66 84</sup> and did not consider cost implications to Medicare.

### Limitations

Our analysis had several limitations. Firstly, we estimated the proportion of patients receiving treatment with cancer drugs for accelerated approval indications using data from Medicare Advantage plans managed by a large health insurer. While previous research has found no systematic differences in cancer prevalence or treatment strategies between Medicare Advantage and traditional Medicare populations, including spending on injectable drugs,<sup>40 41</sup> important differences remain that may affect treatment patterns.<sup>85</sup> For example, a recent study suggested that use of expensive cancer drugs may be lower in Medicare Advantage for indications with inexpensive treatment alternatives.<sup>86</sup> Although this is unlikely to substantially affect our estimates (accelerated approval indications involve novel treatments for which cheaper alternatives are often unavailable), the findings may not be fully generalisable to the broader Medicare population. Additionally, reliance on data from a single insurer may further limit generalisability. Nonetheless, our approach is consistent with earlier studies that use the same nationwide data source.<sup>38</sup>

Secondly, extrapolating the patient survival data relied on the exponential distribution. While this approach is standard in economic evaluations of

treatments for advanced cancers,<sup>51 52 83</sup> alternative parametric distributions may provide a better fit to the underlying data.<sup>87</sup> However, applying such alternatives would require individual participant level data and clinical validation, which were not available.<sup>88</sup> In many cases, even Kaplan-Meier curves were not available (eg, when the most recent overall survival data were extracted from ClinicalTrials.gov). Additionally, the model adopted a limited time horizon, which may have resulted in an underestimation of total life years gained.

Thirdly, in our calculation of additional Medicare spending associated with early access to new cancer drugs, we assumed that the treatment strategies tested in clinical trials represented those used in clinical practice.

Our assessment of patient benefit was limited to overall survival, and we did not consider potential quality of life improvements for drug indications that did not show a survival benefit to patients. Previous research has shown that quality of life improvements are rare,<sup>89</sup> with fewer than 5% of cancer drugs approved by the FDA between 2000 and 2020 offering quality of life benefits to recipients.<sup>90</sup>

Furthermore, we may have overestimated the patient survival benefits of the accelerated approval treatments. Our model assigned life year gains to beneficiaries if overall survival data numerically favoured the accelerated approval drug, irrespective of the statistical significance of the findings.

Lastly, our assessment did not account for potential harms associated with exposure to drug indications without verified benefits or indications that were subsequently withdrawn from the market.<sup>28</sup> Medicare beneficiaries are aged 65 or older and have greater medical complexity, and may be at greater risk of harm from treatment related toxicities.<sup>91</sup> We also did not consider non-drug spending, such as costs related to testing, administration, patient monitoring, other service use, and adverse events, which can be substantial for the Medicare programme. Costs incurred by patients were also not considered.<sup>92</sup>

### Conclusion

From 2012 to 2020, nearly 200 000 Medicare beneficiaries received new cancer drugs during the period between accelerated approval and either conversion to regular approval or withdrawal from the market. More than half of beneficiaries received the new cancer drugs for indications without overall survival benefits, despite some being converted to regular approval, exposing many patients to drugs with limited or unverified clinical benefit. Early access to new cancer drugs through the accelerated approval pathway accounted for an estimated \$20bn in additional Medicare spending, but most beneficiaries derived minimal or no survival gains on this pathway, with only three drug indications accounting for more than two thirds of the total life years gained. These

findings highlight the trade-off between earlier access to new treatments and substantial clinical uncertainty at considerable cost. Strengthening evidence standards to enable timely completion of confirmatory trials may help ensure that early access delivers meaningful benefit to patients, Medicare beneficiaries, and American taxpayers.

#### AUTHOR AFFILIATIONS

<sup>1</sup>Pharmaceutical Policy Lab, London, UK

<sup>2</sup>Department of Health Policy, London School of Economics and Political Science, London, UK

<sup>3</sup>Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA, USA

<sup>4</sup>Harvard Medical School, Boston, MA, USA

<sup>5</sup>Centre for Health Economics, University of York, York, UK

<sup>6</sup>Department of Pharmacy Administration and Clinical Pharmacy, Peking University, Beijing, China

<sup>7</sup>Internal Medicine, Yale School of Medicine, New Haven, CT, USA

<sup>8</sup>Yale Collaboration for Regulatory Rigor Integrity and Transparency, New Haven, CT, USA

<sup>9</sup>Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA

<sup>10</sup>Yale School of Medicine Center for Outcomes Research & Evaluation, New Haven, CT, USA

**Acknowledgements** We thank Courtney Davis (King's College London, UK) and Steve Pearson (Institute for Clinical and Economic Review, US) for their comments on an earlier version of this paper; and Lydia Li and Sophie Mulsant (both from the London School of Economics and Political Science, UK) for their assistance with data extraction.

**Contributors** HN conceived and designed the study and developed the analytical framework. HN, MS, PM, RC, and YZ collected data. HN independently verified all collected data, undertook the analysis, and drafted the manuscript. All authors contributed to subsequent iterations. All authors provided critical input on the manuscript and approved the final version for publication. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. HN is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Transparency: The lead author (HN) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

**Funding** AKW's and RC's effort was funded by a grant from the American Cancer Society (grant RSGI-20-030-01-CPB; Wagner PI). MS's effort was supported by Thomas O Pyle funding for a Harvard Medical School Fellowship in Health Policy and Insurance Research and by the Harvard Pilgrim Health Care Institute.

**Competing interests** All authors have completed the ICMJE uniform disclosure form at [https://www.icmje.org/coi\\_disclosure.pdf](https://www.icmje.org/coi_disclosure.pdf) and declare: support from the American Cancer Society, Thomas O Pyle funding for a Harvard Medical School Fellowship in Health Policy and Insurance Research, and by the Harvard Pilgrim Health Care Institute for the submitted work. HN reports grants from the UK National Institute for Health and Care Research, the European Commission, the US National Institute for Health Care Management Foundation, and the Commonwealth Fund outside the submitted work, and consulting fees from the World Health Organization and Arnold Ventures; HN also reports being an academic adviser to the Analysis section of The BMJ. JSR receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation program (U01FD005938), from the Agency for Healthcare Research and Quality (R01HS022882), and from Arnold Ventures; formerly received research support from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology and from the National Heart, Lung and Blood Institute of the National Institutes of Health (R01HS025164, R01HL14644); JSR was also an expert witness at the request of

Relator's attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen that was settled September 2022. AKW reports grants from the American Cancer Society, Arnold Ventures, and the US Centers for Disease Control, and payment or honorariums from Point32Health, Tampere University, and the Finnish Medical Association. The other authors declare no support from any organisation for the submitted work; no financial relationships with any organisation that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

**Ethics approval** The Harvard Pilgrim Health Care Institutional Review Board determined the study exempt from review because we used publicly available data and deidentified claims data.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. Data may be obtained from a third party and are not publicly available. All data extracted from publicly available sources (accelerated approval status and confirmatory trial characteristics of drug indications in our sample, overall survival findings) are available in the supplementary appendix. Access to data from the Medicare Advantage plans can be directly requested from the data vendor and requires a data use agreement. The economic model will be made available via our institutional website upon publication.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

#### ORCID iDs

Huseyin Naci <https://orcid.org/0000-0002-7192-5751>

Mahnun Shahzad <https://orcid.org/0000-0002-7170-7228>

Peter Murphy <https://orcid.org/0000-0001-8864-1416>

Joseph S Ross <https://orcid.org/0000-0002-9218-3320>

Anita K Wagner <https://orcid.org/0000-0002-1069-6668>

#### REFERENCES

- 1 CFR - code of federal regulations title 21. Available: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.8> [Accessed 16 Oct 2024].
- 2 21 CFR Part 314 Subpart H -- Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses. Available: <https://www.ecfr.gov/current/title-21/part-314/subpart-H> [Accessed 16 Oct 2024].
- 3 Wong AK, Mooghal M, Ramachandran R, *et al*. Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics. *JAMA Netw Open* 2023;6:e2331753. 10.1001/jamanetworkopen.2023.31753
- 4 Fleming TR. Surrogate Endpoints And FDA's Accelerated Approval Process. *Health Aff (Millwood)* 2005;24:67–78. 10.1377/hlthaff.24.1.67
- 5 Wallach JD, Yoon S, Doernberg H, *et al*. Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments. *JAMA* 2024;331:1646. 10.1001/jama.2024.4175
- 6 Ladani A, Schmitt AM, Speich B, *et al*. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. *JAMA Netw Open* 2020;3:e2024406. 10.1001/jamanetworkopen.2020.24406
- 7 Naci H, Wouters OJ, Gupta R, *et al*. Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval. *Milbank Q* 2017;95:261–90. 10.1111/1468-0009.12261

8 Downing NS, Aminawung JA, Shah ND, *et al*. Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012. *JAMA* 2014;311:368. 10.1001/jama.2013.282034

9 Herder M. Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency. *Milbank Q* 2019;97:820-57. 10.1111/1468-0009.12413

10 Woloshin S, Schwartz LM, White B, *et al*. The Fate of FDA Postapproval Studies. *N Engl J Med* 2017;377:1114-7. 10.1056/NEJMmp1705800

11 US Government Accountability Office. Drug safety: fda expedites many applications, but data for postapproval oversight need improvement. US GAO. Available: <https://www.gao.gov/products/gao-16-192> [Accessed 16 Oct 2024].

12 US Department of Health and Human Services. Delays in Confirmatory Trials for Drug Applications Granted FDA's Accelerated Approval Raise Concerns. 2022. Available: <https://oig.hhs.gov/reports/all/2022/delays-in-confirmatory-trials-for-drug-applications-granted-fdas-accelerated-approval-raise-concerns/> [accessed 5 Dec 2025]

13 Mahase E. FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway. *BMJ* 2021;374:n1898. 10.1136/bmj.n1898

14 Deshmukh AD, Kesselheim AS, Rome BN. Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021. *JAMA Health Forum* 2023;4:e230217. 10.1001/jamahealthforum.2023.0217

15 Naci H, Smalley KR, Kesselheim AS. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. *JAMA* 2017;318:626. 10.1001/jama.20179415

16 Gyawali B, Rome BN, Kesselheim AS. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. *BMJ* 2021;374:n1959. 10.1136/bmj.n1959

17 Prasad V, Kim C, Buroto M, *et al*. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. *JAMA Intern Med* 2015;175:1389-98. 10.1001/jamainternmed.2015.2829

18 Haslam A, Hey SP, Gill J, *et al*. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. *Eur J Cancer* 2019;106:196-211. 10.1016/j.ejca.2018.11.012

19 Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. *J Clin Oncol* 2009;27:2874-80. 10.1200/JCO.2008.20.4107

20 Kovac B, Jin X, Kennedy SA, *et al*. Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis. *JAMA Intern Med* 2018;178:1586-96. 10.1001/jamainternmed.2018.4710

21 Kim C, Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. *JAMA Intern Med* 2015;175:1992-4. 10.1001/jamainternmed.2015.5868

22 Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. *JAMA Intern Med* 2019;179:906-13. 10.1001/jamainternmed.2019.0462

23 Liu ITT, Kesselheim AS, Cliff ERS. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval. *JAMA* 2024;331:1471. 10.1001/jama.2024.2396

24 Wallach JD, Ross JS, Naci H. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements. *Clin Trials* 2018;15:219-29. 10.1177/1740774518770648

25 Beaver JA, Howie LJ, Pelosof L, *et al*. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review. *JAMA Oncol* 2018;4:849-56. 10.1001/jamaoncol.2017.5618

26 Johnson JR, Ning Y-M, Farrell A, *et al*. Accelerated Approval of Oncology Products: The Food and Drug Administration Experience. *J Natl Cancer Inst* 2011;103:636-44. 10.1093/jnci/djr062

27 Kesselheim AS, Avorn J. The most transformative drugs of the past 25 years: a survey of physicians. *Nat Rev Drug Discov* 2013;12:425-31. 10.1038/nrd3977

28 Parikh RB, Hubbard RA, Wang E, *et al*. Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval. *JAMA Oncol* 2023;9:567-9. 10.1001/jamaoncol.2022.7770

29 Gellad WF, Kesselheim AS. Accelerated Approval and Expensive Drugs - A Challenging Combination. *N Engl J Med* 2017;376:2001-4. 10.1056/NEJMmp1700446

30 An overview of medicare. KFF; 2019. Available: <https://www.kff.org/medicare/issue-brief/an-overview-of-medicare/> [Accessed 8 Jul 2025].

31 Cancer of any site - cancer stat facts. SEER. Available: <https://seer.cancer.gov/statfacts/html/all.html> [Accessed 2 Dec 2024].

32 Kyle MA, Dusetzina SB, Keating NL. Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020. *JAMA Netw Open* 2022;5:e2221468. 10.1001/jamanetworkopen.2022.21468

33 Rome BN, Feldman WB, Kesselheim AS. Medicare Spending on Drugs With Accelerated Approval, 2015-2019. *JAMA Health Forum* 2021;2:e213937. 10.1001/jamahealthforum.2021-3937

34 Husereau D, Drummond M, Augustovski F, *et al*. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. *BMJ* 2022;376:e067975. 10.1136/bmj-2021-067975

35 Medicare part D drug spending dashboard. CMS Data. Available: <https://data.cms.gov/tools/medicare-part-d-drug-spending-dashboard> [Accessed 21 Jul 2025].

36 Medicare part B drug spending dashboard. CMS Data. Available: <https://data.cms.gov/tools/medicare-part-b-drug-spending-dashboard> [Accessed 21 Jul 2025].

37 Ballreich J, Socal M, Bennett CL, *et al*. Medicare Spending on Drugs With Accelerated Approval. *Ann Intern Med* 2022;175:938-44. 10.7326/M21-4442

38 Shahzad M, Naci H, Wagner AK. Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval. *JAMA Intern Med* 2021;181:1673-5. 10.1001/jamainternmed.2021.589

39 Ochieng N, Cubanski J. A snapshot of sources of coverage among medicare beneficiaries. KFF; 2024. Available: <https://www.kff.org/medicare/issue-brief/a-snapshot-of-sources-of-coverage-among-medicare-beneficiaries/> [Accessed 21 Jul 2025].

40 Newhouse JP, Price M, McWilliams JM, *et al*. HOW MUCH FAVORABLE SELECTION IS LEFT IN MEDICARE ADVANTAGE? *Am J Health Econ* 2015;1:1-26. 10.1162/AJHE\_a\_00001

41 Schwartz AL, Zlaoui K, Foreman RP, *et al*. Health Care Utilization and Spending in Medicare Advantage vs Traditional Medicare. *JAMA Health Forum* 2021;2:e214001. 10.1001/jamahealthforum.2021.4001

42 Naci H, Guan X, Woloshin S, *et al*. Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs. *JAMA Intern Med* 2021;181:1521. 10.1001/jamainternmed.2021.3505

43 Naci H, Zhang Y, Woloshin S, *et al*. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. *Lancet Oncol* 2024;25:760-9. 10.1016/S1470-2045(24)00152-9

44 Skydel JJ, Egilman AC, Wallach JD, *et al*. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017. *JAMA Health Forum* 2022;3:e221158. 10.1001/jamahealthforum.2022.1158

45 How BLS Measures Price Change for Medical Care Services in the Consumer Price Index. Bureau of Labor Statistics. Available: <https://www.bls.gov/cpi/factsheets/medical-care.htm> [Accessed 14 Mar 2025].

46 Williams C, Lewsey JD, Mackay DF, *et al*. Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling. *Med Decis Making* 2017;37:427-39. 10.1177/0272989X16670617

47 Woods B, Sideris E, Palmer S, *et al*. NICE DSU technical support document 19: Partitioned survival analysis for decision modelling in health care: a critical review. Report by the Decision Support Unit.

48 Woods B, Sideris E, Palmer S, *et al*. Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now. *Value Health* 2020;23:1613-21. 10.1016/j.jval.2020.08.2094

49 Bagust A, Beale S. Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach. *Med Decis Making* 2014;34:343-51. 10.1177/0272989X13497998

50 Latimer NR. Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data. *Med Decis Making* 2013;33:743-54. 10.1177/0272989X12472398

51 Gallacher D, Auguste P, Connock M. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017. *Int J Technol Assess Health Care* 2019;35:160-7. 10.1017/S0266462319000175

52 Bell Gorrod H, Kearns B, Stevens J, *et al*. A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement. *Med Decis Making* 2019;39:899-909. 10.1177/0272989X19881967

53 Value assessment framework. ICER. Available: <https://icer.org/our-approach/methods-process/value-assessment-framework/> [Accessed 21 Jul 2025].

54 Vanness D, Lomas J, Ahn H. A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States. *Ann Intern Med* 2021;174:25-32. 10.7326/M20-1392

55 Wallach JD, Ramachandran R, Bruckner T, *et al*. Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic

Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018. *JAMA Netw Open* 2021;4:e2133601. 10.1001/jamanetworkopen.2021.33601

56 Dagher R, Johnson J, Williams G, et al. Accelerated approval of oncology products: a decade of experience. *J Natl Cancer Inst* 2004;96:1500-9. 10.1093/jnci/djh279

57 Lakdawalla DN, Chou JW, Linthicum MT, et al. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer. *JAMA Oncol* 2015;1:196-202. 10.1001/jamaonc.2015.0203

58 Forrest R, Lagarde M, Aggarwal A, et al. Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. *Lancet Oncol* 2024;25:1635-43. 10.1016/S1470-2045(24)00596-5

59 Jena AB, Zhang J, Lakdawalla DN. The Trade-off Between Speed and Safety in Drug Approvals. *JAMA Oncol* 2017;3:1465-6. 10.1001/jamaonc.2016.3337

60 US Food and Drug Administration. Accelerated approval and considerations for determining whether a confirmatory trial is underway. 2025. Available: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/accelerated-approval-and-considerations-determining-whether-confirmatory-trial-underway> [Accessed 13 Mar 2025].

61 Fashoyin-Aje LA, Mehta GU, Beaver JA, et al. The On- and Off-Ramps of Oncology Accelerated Approval. *N Engl J Med* 2022;387:1439-42. 10.1056/NEJMmp2208954

62 Shahzad M, Naci H, Wagner AK. Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway. *JAMA* 2023;329:760-1. 10.1001/jama.2023.0625

63 Dawoud D, Naci H, Ciani O, et al. Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. *BMJ* 2021;374:n2191. 10.1136/bmj.n2191

64 Bujkiewicz S, Thompson JR, Riley RD, et al. Bayesian meta-analytical methods to incorporate multiple surrogate endpoints in drug development process. *Stat Med* 2016;35:1063-89. 10.1002/sim.6776

65 Wallach JD, Zhang AD, Skydel JJ, et al. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval. *JAMA Netw Open* 2021;4:e2133667. 10.1001/jamanetworkopen.2021.33667

66 Salcher-Konrad M, Nguyen M, Savovic J, et al. Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: A Meta-Analysis. *JAMA Netw Open* 2024;7:e2436230. 10.1001/jamanetworkopen.2024.36230

67 Ballreich J, Socal M, Bennett CL, et al. Accelerated approval drug labels often lack information for clinical decision-making. *Pharmacotherapy* 2023;43:300-4. 10.1002/phar.2789

68 Kaltenboeck A, Mehlman A, Pearson SD. Potential policy reforms to strengthen the accelerated approval pathway. *J Comp Eff Res* 2021;10:1177-86. 10.2217/cer-2021-0184

69 Del Paggio JC, Sullivan R, Schrag D, et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. *Lancet Oncol* 2017;18:887-94. 10.1016/S1470-2045(17)30415-1

70 Frank RG, Shahzad M, Emanuel EJ. Accelerated Approval Of Cancer Drugs: No Economic Reward For Drug Makers That Conduct Confirmatory Trials. *Health Aff (Millwood)* 2022;41:1273-80. 10.1377/hlthaff.2022.00119

71 Neumann PJ, Crummer E, Chambers JD, et al. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval. *Milbank Q* 2023;101:1047-75. 10.1111/1468-0009.12670

72 Frank RG, Emanuel EJ. Paying for Cancer Drugs That Prove Their Benefit. *JAMA* 2021;326:1579. 10.1001/jama.2021.18308

73 Mooghal M, Mitchell AP, Skydel JJ, et al. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study. *bmjmed* 2024;3:e000802. 10.1136/bmjmed-2023-000802

74 Parikh RB, Ulloa-Pérez E, Kurian M, et al. Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies. *JAMA Netw Open* 2025;8:e2520726. 10.1001/jamanetworkopen.2025.20726

75 Cliff ERS, Rome RS, Kesselheim AS, et al. National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval. *JAMA Netw Open* 2023;6:e2343285. 10.1001/jamanetworkopen.2023.43285

76 Wei Y, Zhang Y, Xu Z, et al. Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020. *Lancet Reg Health West Pac* 2024;45:101055. 10.1016/j.lanwpc.2024.101055

77 Irama-Brummell AM, Marciniuk FL, Wagner AK, et al. Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis. *Lancet Reg Health Am* 2023;22:100506. 10.1016/j.lana.2023.100506

78 Salcher-Konrad M, Naci H, Davis C. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States. *Milbank Q* 2020;98:1219-56. 10.1111/1468-0009.12476

79 Cherla A, Naci H, Kesselheim AS, et al. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. *JAMA Intern Med* 2021;181:490. 10.1001/jamainternmed.2020.8441

80 Cramer A, Sørup FKH, Christensen HR, et al. Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU? *Lancet Oncol* 2023;24:e385-94. 10.1016/S1470-2045(23)00357-1

81 Sachs RE, Jazowski SA, Gavulic KA, et al. Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits. *J Health Polit Policy Law* 2022;47:673-90. 10.1215/03616878-10041107

82 Sachs RE, Gavulic KA, Donohue JM, et al. Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval. *JAMA Health Forum* 2021;2:e213177. 10.1001/jamahealthforum.2021.3177

83 Benedict Á, Szabó G, Marcellz K, et al. Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model. *J Natl Compr Canc Netw* 2024;22:382-9. 10.6004/jnccn.2024.7010

84 Soni PD, Hartman HE, Dessim RT, et al. Comparison of Population-Based Observational Studies With Randomized Trials in Oncology. *JCO* 2019;37:1209-16. 10.1200/JCO.18.01074

85 Agarwal R, Connolly J, Gupta S, et al. Comparing Medicare Advantage And Traditional Medicare: A Systematic Review. *Health Aff (Millwood)* 2021;40:937-44. 10.1377/hlthaff.2020.02149

86 Bradley CJ, Liang R, Lindrooth RC, et al. High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare. *JAMA Health Forum* 2025;6:e244868. 10.1001/jamahealthforum.2024.4868

87 Latimer NR, Adler AI. Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness. *bmjmed* 2022;1:e000094. 10.1136/bmjmed-2021-000094

88 Latimer N. . NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. Report by the Decision Support Unit; 2011.2. 20.

89 Rupp T, Zuckerman D. Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints. *JAMA Intern Med* 2017;177:276-7. 10.1001/jamainternmed.2016.7761

90 Gloy V, Schmitt AM, Dublin P, et al. The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020. *Int J Cancer* 2023;152:2474-84. 10.1002/ijc.34473

91 Bird ST, Tian F, Flowers N, et al. Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries. *JAMA Oncol* 2020;6:248-54. 10.1001/jamaonc.2019.3994

92 Shih YCT, Xu Y, Liu L, et al. Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries. *JCO* 2017;35:2482-9. 10.1200/JCO.2017.72.3742

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/bmjmed-2025-001934>).